From Innovation to Routine Care 

Translation of innovation to research and care is RC2NB’s mission. This workstream provides the framework to systematically evaluate patient-relevant benefits resulting from therapeutic and diagnostic innovations developed at RC2NB.

We take advantage of the unique combination of interdisciplinary clinical and methodological expertise at RC2NB with long-standing experience in clinical trial design and conduct, established and novel data infrastructures, and support and collaboration through a wide network of stakeholders locally, nationally and internationally.

We aim to create a learning system that combines high-quality real-world data with randomization integrated into usual care to continuously evaluate health care decisions in pragmatic trials. This yields high-quality evidence on patient-relevant benefits and accelerates the implementation of diagnostic and therapeutic innovation to real-world care settings.

We use data collected from routine care and data on digital, imaging and fluid biomarkers. We leverage complex high-quality data from the SMSC, an established nationwide cohort study, and aim to integrate approaches allowing decentralized, remote trials in an effort to minimize research burden for investigational teams and, most importantly, for patients.

We rely on state-of-the-art clinical epidemiology and meta-research methods to continuously develop, evaluate, and optimize this real-world evidence-generating system to inform care decisions.